<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">JBM</journal-id><journal-title-group><journal-title>Journal of Biosciences and Medicines</journal-title></journal-title-group><issn pub-type="epub">2327-5081</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/jbm.2022.1010004</article-id><article-id pub-id-type="publisher-id">JBM-120358</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biomedical&amp;Life Sciences</subject></subj-group></article-categories><title-group><article-title>
 
 
  Management of Secondary Leyll Syndrome Due to Anti-Covid Vaccine in a Case, at the Renaissance University Teaching Hospital, Ndjamena (CHAD)
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Traoré</surname><given-names>Sory</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Adamou</surname><given-names>Abassi Mana</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Abdelsalam</surname><given-names>Hissein Hassan</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Kader</surname><given-names>Ndjaye</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Nouradine</surname><given-names>Abakar</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Abdesalam</surname><given-names>Mahamt Bahar</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mahamat</surname><given-names>Ali Bolti</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ngamai</surname><given-names>Kotyadé</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mwabanyol</surname><given-names>Loobe Regis</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Michel</surname><given-names>Slama</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Hamit</surname><given-names>Mahamat Alio</given-names></name><xref ref-type="aff" rid="aff7"><sup>7</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Anesthesia-Resuscitation Department of the Renaissance University Teaching Hospital, N’Djamena, Chad</addr-line></aff><aff id="aff4"><addr-line>Surgery Department of N’Djamena Renaissance University Teaching Hospital, N’Djamena, Chad</addr-line></aff><aff id="aff3"><addr-line>Internal Medicine Department, N’Djamena Renaissance University Teaching Hospital, N’Djamena, Chad</addr-line></aff><aff id="aff7"><addr-line>Laboratory Department of the Renaissance University Teaching Hospital of N’Djamena, N’Djamena, Chad</addr-line></aff><aff id="aff5"><addr-line>Ophthalmology Department of the N’Djamena Renaissance University Teaching Hospital, N’Djamena, Chad</addr-line></aff><aff id="aff6"><addr-line>Head of Resuscitation Department CHU Amiens-Picardie, Amiens, France</addr-line></aff><aff id="aff2"><addr-line>Emergency Department of the N’Djamena Renaissance University Teaching Hospital, N’Djamena, Chad</addr-line></aff><pub-date pub-type="epub"><day>01</day><month>10</month><year>2022</year></pub-date><volume>10</volume><issue>10</issue><fpage>47</fpage><lpage>54</lpage><history><date date-type="received"><day>25,</day>	<month>July</month>	<year>2022</year></date><date date-type="rev-recd"><day>9,</day>	<month>October</month>	<year>2022</year>	</date><date date-type="accepted"><day>12,</day>	<month>October</month>	<year>2022</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Introduction: Lyell’s syndrome (SL), called Toxic Epidermal Necrolysis is one of the most serious forms of medication accidents. It is an acute, rare pathology, its incidence is estimated at 1 to 2 cases out of one million inhabitants per year and its evolution can be fatal. 
  Materials and Methods: We report the observation of a 60-year-old patient, with no significant pathological history, admitted to our intensive care unit at the Renaissance University Teaching Hospital in N’Djamena for the treatment of Toxic Epidermal Necrolysis. In whom the onset of symptoms dates back to few hours after vaccination against COVID-19 with Ag Johnson and Johnson. 
  Results: An ophthalmology opinion was requested and the patient was put on Fucithalmic. In our case, in addition to the advanced age of the patient (60 years old), her SCORTEN was ≥5. 
  Conclusion: The late management as well as the absence of a specific department for severe burns, which condition the presence of a technical plate was fatal to her despite multidisciplinary care: Resuscitators, Traumato-Orthopedist and ophthalmologist.
 
</p></abstract><kwd-group><kwd>Lyell Syndrome</kwd><kwd> Renaissance University Teaching Hospital</kwd><kwd> N’Djamena</kwd><kwd> Symptomatology</kwd><kwd> Vaccination</kwd><kwd> Covid-19</kwd><kwd> SCORTEN</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Lyell’s syndrome (SL), called Toxic Epidermal Necrolysis (TEN) is one of the most serious forms of medication accidents. It is an acute but rare pathology, its incidence is estimated at 1 to 2 cases per million inhabitants per year and its evolution can be fatal [<xref ref-type="bibr" rid="scirp.120358-ref1">1</xref>]. In France, about 120 cases were recorded each year. LS was first described in 1956 by a Scottish dermatologist Alan Lyell in four patients [<xref ref-type="bibr" rid="scirp.120358-ref2">2</xref>]. The disease is manifested by a more or less feverish rash with areas of bullous detachment reaching by definition more than 30% of the body surface. This appearance is that of an extensive deep second-degree burn [<xref ref-type="bibr" rid="scirp.120358-ref3">3</xref>]. TEN and Stevens Johnson Syndrome (SJS) are the same condition but differ in severity. Cutaneous involvement of 10% is the threshold beyond which an increase in mortality is observed. Thus, we attribute to SJS (reputed to be less severe) a skin lesion less than or equal to 10% [<xref ref-type="bibr" rid="scirp.120358-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.120358-ref4">4</xref>]. Histologically, TEN is characterized by keratinocyte necrosis and alteration of the dermoepidermal junction [<xref ref-type="bibr" rid="scirp.120358-ref5">5</xref>]. According to Siah et al. [<xref ref-type="bibr" rid="scirp.120358-ref5">5</xref>], several genetic, immunological and viral factors are supposed to be involved in the pathophysiology of LS, but remain poorly elucidated. Multivisceral involvement (ocular, respiratory, renal, haematological, etc.) complicates the clinical picture [<xref ref-type="bibr" rid="scirp.120358-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.120358-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.120358-ref7">7</xref>]. In addition, the management of systemic involvement in the TEN is multidisciplinary in the intensive care units for severe burns (or in the intensive care unit in our case). According to several studies [<xref ref-type="bibr" rid="scirp.120358-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.120358-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.120358-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.120358-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.120358-ref9">9</xref>], early multidisciplinary management reduces the mortality rate and is currently below 20%. For [<xref ref-type="bibr" rid="scirp.120358-ref5">5</xref>], this remarkable progress is at the cost of good care in intensive care and restrictive nursing.</p><p>We report the observation of a 60-year-old patient, with no significant pathological history, admitted on 09/04/2022 to our intensive care unit at the Renaissance University Teaching Hospital in N’Djamena for the treatment of Toxic Epidermal Necrolysis (TEN) following a vaccination against Covid-19 (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p></sec><sec id="s2"><title>2. Patient and Observation</title><p>The onset of symptoms dates back to the evening of 03/24/2022 after vaccination against COVID-19 with Ag Johnson and Johnson, Lot number 652 which expires in 10/2023, marked by the occurrence of a fever with chills accompanied by generalized pruritus followed by bullous rashes giving progressively extensive toxic epidermal necrolysis to the whole body associated with dysphagia to solids occurring a few hours later, having motivated a consultation in a local Health Center where she would have benefited medical treatment based on Dexamethasone and Chlorpheniramine without success. It was in the face of the worsening of the symptoms that she was referred to the R-UTH for better care. On</p><p>admission, there is an alteration in general condition, preserved consciousness, PA: 132/72 mmHg; HR: 125 bpm; SpO<sub>2</sub>: 97% on room air; eupneic; a diuresis preserved with very dark urine and a fever of 40.5˚C. Extensive epidermal necrolysis with Burnt Body Surface (SCB) estimated at 100% including 40% to 50% of deep 2nd degree with positive NIKOLSKI’s sign. There was also infla-mmation of the oropharynx and synechia of the eyelids with significant tearing.</p></sec><sec id="s3"><title>3. Biology</title><p>NFS: Leukocytes: 5100/mm<sup>3</sup>, Hemoglobin: 9.1 g/dL hypochromic microcyte, Platelets: 196,000/mm<sup>3</sup>; GS/HR: A+; an inflammatory syndrome with CRP: 100 mg/L; impaired renal function: Urea: 17.85 mmol/L, Creatinemia: 310.8 &#181;mol/L (GFR: 17.095 ml/min); ionic disorders (Na<sup>+</sup>: 123 mmol/l, K<sup>+</sup>: 2.3 mmol/l, Cl<sup>−</sup>: 82.30 mmol/l) and hypoalbuminemia at 21.2 g/l.</p><p>The TEN is retained before the clinical, anamnestic and biological arguments with a SCORTEN ≥ 5.</p><p>Mesasure taken:</p><p>&#173; Septic isolation;</p><p>&#173; Oxygen therapy by bezel;</p><p>&#173; Placement of a VVC in the right femoral and filling with Ringer Lactate and Nacl 0.9% according to the Parkland formula;</p><p>&#173; Placement of an arterial catheter in the left radial for invasive blood pressure</p><p>&#173; Analgesic: paracetamol, tramadol and morphine then Ketamine with PSE;</p><p>&#173; Antibiotic therapy: Meropenem and Metronidazol;</p><p>&#173; Correction of ionic disorders by supplying sodium and potassium ions;</p><p>&#173; Anticoagulant: Enoxaparin;</p><p>&#173; Gastric protection: Omeprozole;</p><p>&#173; Enteral/SNG and Parenteral Nutrition with Perikabiven;</p><p>&#173; Daily dressings in bed.</p><p>An ophthalmology opinion was requested and put on Fucithalmic.</p><p>A J1: patient stable on hemodynamic and respiratory plan under O<sub>2</sub> 2 l/m, conscience conserved and apyretic.</p><p>On D3: Control assessment: Hb deglobulization: 8.4 g/dl, slight improvement in renal function: creat = 243 &#181;mol/l, urea = 15 mmol/l.</p><p>On D5: worsening by respiratory distress, hemodynamic instability and hypothermia</p><p>CAT: O2/MHC, and amine vasopressor (noradrenaline).</p><p>Evolution was marked by septic shock refractory to noradrenaline and the patient died on D6 of hospitalization (04/14/22) at 01:05 in a picture of septic shock with multi-visceral failure.</p></sec><sec id="s4"><title>4. Discussion</title><p>TEN occurs at any age, with a slightly elevated incidence in the elderly [<xref ref-type="bibr" rid="scirp.120358-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.120358-ref7">7</xref>]. As in our case, Bastusji-Garin [<xref ref-type="bibr" rid="scirp.120358-ref10">10</xref>] and Bonnetblanc et al. [<xref ref-type="bibr" rid="scirp.120358-ref11">11</xref>] reported an incidence of LS 2.7 times higher in subjects over 60 years old than in a younger population. The elderly present a fragile ground (pathological antecedents), often polymedicated. The originality of our observation lies in the rarity of severe drug eruption due to the anti-COVID-19 vaccine and particularly Lyell’s syndrome. Indeed, to our knowledge, this is the first case reported in Chad during the anti-COVID-19 vaccination campaign with the Jhonson and Jhonson vaccine. Cases of Toxidermia linked to vaccines have been reported by certain observations, in particular linked to: Pzifer, Moderna, Sinopharm, as is the case with the following authors: Elboraey et al. [<xref ref-type="bibr" rid="scirp.120358-ref12">12</xref>] in Egypt, Mardani et al. [<xref ref-type="bibr" rid="scirp.120358-ref13">13</xref>] in Iran and Dash et al. [<xref ref-type="bibr" rid="scirp.120358-ref14">14</xref>] in India. As we note, all the different types of COVID-19 vaccines can be responsible for this syndrome.</p><p>Drug combinations are also responsible for LS, but in our case, this possibility was ruled out by the anamnesis. Our patient was not polymedicated.</p><p>Several results reported a slight female predominance, with a sex ratio of 0.6 [<xref ref-type="bibr" rid="scirp.120358-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.120358-ref15">15</xref>] [<xref ref-type="bibr" rid="scirp.120358-ref16">16</xref>] [<xref ref-type="bibr" rid="scirp.120358-ref17">17</xref>] and indeed our case is female. The work, among others, of [<xref ref-type="bibr" rid="scirp.120358-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.120358-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.120358-ref18">18</xref>] [<xref ref-type="bibr" rid="scirp.120358-ref19">19</xref>] [<xref ref-type="bibr" rid="scirp.120358-ref20">20</xref>] has shown that patients suffering from HIV, systemic lupus erythematosus or having undergone a bone marrow transplant (immunocompromised) are subjects at risk of SJS or TEN. In the same vein, Mokline et al. [<xref ref-type="bibr" rid="scirp.120358-ref21">21</xref>] have shown that in addition to the factors including the comorbidities mentioned above, advanced age, the surface area of the skin detachment, the delay in diagnosis and treatment, the late discontinuation of the drug in question and the proven complications, in particular infectious, are formidable because they are responsible for a high mortality rate. Although our patient was of an advanced age and did not present any of these risk factors, the onset of the symptoms dates back to the evening after a vaccination against COVID-19 (Ag Johnson and Johnson) marked by the occurrence of a fever with chills accompanied generalized pruritus followed by bullous rashes giving progressively extensive toxic epidermal necrolysis throughout the body associated with dysphagia to solids. However, there was a delay in diagnosis and good care because our patient was consulted in a local health center where she received medical treatment based on Dexamethasone and Chlorpheniramine. The first drug is a nonsteroidal anti-inflammatory drug from the corticosteroid (glucocorticoid) family, and the second is an antihistamine from the pyridine class. Several studies, among others 12, 13 and 14, have shown the role of vaccination, although very rare, in the occurrence of TEN. Although in our case neither Dexamethasone nor Chlorpheniramine are incriminated, in the literature [<xref ref-type="bibr" rid="scirp.120358-ref22">22</xref>] [<xref ref-type="bibr" rid="scirp.120358-ref23">23</xref>] [<xref ref-type="bibr" rid="scirp.120358-ref24">24</xref>] [<xref ref-type="bibr" rid="scirp.120358-ref25">25</xref>] the drugs most frequently imputed are anti-infective sulfonamides, anticonvulsants, non-steroidal anti-inflammatory drugs and allopurinol. For [<xref ref-type="bibr" rid="scirp.120358-ref24">24</xref>] [<xref ref-type="bibr" rid="scirp.120358-ref25">25</xref>], the occurrence of TEN is independent of the dose received and a minor exposure may be sufficient to cause the disease. In the same order, several studies have instead incriminated anti-infective sulfonamides [<xref ref-type="bibr" rid="scirp.120358-ref23">23</xref>] [<xref ref-type="bibr" rid="scirp.120358-ref24">24</xref>] [<xref ref-type="bibr" rid="scirp.120358-ref25">25</xref>] [<xref ref-type="bibr" rid="scirp.120358-ref26">26</xref>]. On the other hand, for the authors Surbled et al., Melde et al., Mandal et al., Mame et al. [<xref ref-type="bibr" rid="scirp.120358-ref27">27</xref>] [<xref ref-type="bibr" rid="scirp.120358-ref28">28</xref>] [<xref ref-type="bibr" rid="scirp.120358-ref29">29</xref>] [<xref ref-type="bibr" rid="scirp.120358-ref30">30</xref>] almost all of the risks are incriminated with particular frequency for penicillins, followed by quinolones, vancomycin, macrolides and antituberculosis drugs. As for most of the studies [<xref ref-type="bibr" rid="scirp.120358-ref31">31</xref>] [<xref ref-type="bibr" rid="scirp.120358-ref32">32</xref>] [<xref ref-type="bibr" rid="scirp.120358-ref33">33</xref>] [<xref ref-type="bibr" rid="scirp.120358-ref34">34</xref>] [<xref ref-type="bibr" rid="scirp.120358-ref35">35</xref>], the diagnosis of our case is based on the clinic, the anamnestic arguments and the data of the biological examinations. There is currently no specific treatment of demonstrated validity [<xref ref-type="bibr" rid="scirp.120358-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.120358-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.120358-ref35">35</xref>].</p><p>Systemic corticosteroid therapy remains controversial; various immunosuppressive treatments (cyclophosphamide, ciclosporin) have been tried in a few cases [<xref ref-type="bibr" rid="scirp.120358-ref11">11</xref>], without proven proof of their effectiveness. The benefits of high doses of intravenous immunoglobulins have not been confirmed [<xref ref-type="bibr" rid="scirp.120358-ref18">18</xref>]. The prognosis of SL remains reserved, it depends on several pejorative factors including advanced age, the surface of the skin detachment, the delay in diagnosis and management, the late discontinuation of the drug and the complications, in particular infectious, proven and formidable. Because they are responsible for a high mortality rate [<xref ref-type="bibr" rid="scirp.120358-ref35">35</xref>] [<xref ref-type="bibr" rid="scirp.120358-ref36">36</xref>]. The most important sequelae are dyschromic scars such as hyperpigmentation and corneal sequelae (cases that may require a graft, and recur on the graft). Whatever the incriminated drug, the management is multidisciplinary, and requires hospitalization in an intensive care unit. It is mainly based on rehydration, nutrition, local skin care and mucous membranes (oral, ocular and genital), as well as the treatment of secondary infections [<xref ref-type="bibr" rid="scirp.120358-ref34">34</xref>] [<xref ref-type="bibr" rid="scirp.120358-ref35">35</xref>] [<xref ref-type="bibr" rid="scirp.120358-ref36">36</xref>]. The severity and the prognosis (vital or not) are evaluated by the SCORTEN [<xref ref-type="bibr" rid="scirp.120358-ref31">31</xref>] [<xref ref-type="bibr" rid="scirp.120358-ref33">33</xref>] [<xref ref-type="bibr" rid="scirp.120358-ref34">34</xref>] [<xref ref-type="bibr" rid="scirp.120358-ref35">35</xref>] [<xref ref-type="bibr" rid="scirp.120358-ref36">36</xref>]. In our case, in addition to the advanced age of the patient (60 years old), the late management and the absence of a specific service for severe burns, which determines the presence of a technical platform, were fatal to her. Moreover, the SCORTEN of our patient was ≥5.</p></sec><sec id="s5"><title>5. Conclusion</title><p>Lyell’s syndrome or toxic epidermal necrolysis is a rare but serious pathology, responsible for significant morbidity and mortality. Early and multidisciplinary care in an intensive care unit dedicated solely to burns patients improves the prognosis of this condition. Through this observation, we are appealing to the country’s health authorities to be more vigilant about the side effects linked to vaccines, and above all an early and adequate management strategy. For doctors, the thoughtless and unfounded drug prescription especially that of antibiotics, could lead to the risk of the occurrence of TEN. To the authorities responsible for Health in Chad, the creation of a center dedicated to severe burns is essential. All these means of prevention will help to further reduce the frequency of this condition and improve the prognosis.</p></sec><sec id="s6"><title>Acknowledgements</title><p>Our gratitude goes to Mr Yerima Mahamat Isma for his invaluable help in translating the study into English.</p></sec><sec id="s7"><title>Conflicts of Interest</title><p>Conflict of interest was not revealed in this study.</p></sec><sec id="s8"><title>Author’s Contribution</title><p>All authors contributed to the conduct of this work and to the drafting of the manuscript. All authors have read and approved the final version of the manuscript.</p></sec><sec id="s9"><title>Cite this paper</title><p>Sory, T., Mana, A.A., Hassan, A.H., Ndjaye, K., Abakar, N., Bahar, A.M., Bolti, M.A., Kotyad&#233;, N., Regis, M.L., Slama, M. and Alio, H.M. (2022) Management of Secondary Leyll Syndrome Due to Anti-Covid Vaccine in a Case, at the Renaissance University Teaching Hospital, Ndjamena (CHAD). Journal of Biosciences and Medicines, 10, 47-54. https://doi.org/10.4236/jbm.2022.1010004</p></sec></body><back><ref-list><title>References</title><ref id="scirp.120358-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Couadau, E., Carles, M. and Ichai, C. (2001) Troubles cutanés en réanimation. Conférence d’Actualisation, Elsevier, Paris, 551-570.</mixed-citation></ref><ref id="scirp.120358-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Lyell, A. (1956) Toxic Epidermal Necrolysis: An Eruption Resembling Scalding of the Skin. British Journal of Dermatology, 68, 355-361.https://doi.org/10.1111/j.1365-2133.1956.tb12766.x</mixed-citation></ref><ref id="scirp.120358-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Moussala, M., Behar Cohen, P., Dighiero, P. and Renard, G. (2002) Le syndrome de Lyell et ses manifestations ophtalmologiques en milieu camerounais. Journal Francais d’Ophtalmologie, 23, 229-237.</mixed-citation></ref><ref id="scirp.120358-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Siham, D. (2005) Syndrome de Lyell et syndrome de Stevens-Johnson: l’Expérience du service de dermatologie du centre hospitalier universitaire Ibn-Sina, Rabat, Maroc. Thèse de Doctorat, Université de Rabah, Rabah, 150.</mixed-citation></ref><ref id="scirp.120358-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Siah, S., Baite, A., Bakkali, H., Atmani, M., Ababou, K. and Ihrai, H. (2009) Prise en Charge du Syndrome de Lyell ou Necrolyse Epidermique Toxique. Annals of Burns and Fire Disasters, 22, 142-146.</mixed-citation></ref><ref id="scirp.120358-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Bismuth, C. (1981) Les possibilités de réanimation dans les syndromes allergiques graves. Revue Francaise d’Allergologie et d’Immunologie Clinique, 21, 83-86. https://doi.org/10.1016/S0335-7457(81)80004-4</mixed-citation></ref><ref id="scirp.120358-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Chosidow, O., Roujeau, J.-C. and Revuz, J. (1991) Syndrome de Lyell (nécrose épidermique toxique). EMC, 12450, A10.</mixed-citation></ref><ref id="scirp.120358-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Bastuji-Garin, S., et al. (1993) Clinical Classification of Cases of Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome and Erytheme Multiforme. Archives of Dermatology, 129, 92-96. https://doi.org/10.1001/archderm.129.1.92</mixed-citation></ref><ref id="scirp.120358-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Paquet, P., Jacob, E., Damas, P. and Piérard, G.E. (2001) Treatment of Drug-Induced Toxic Epidermal Necrolysis (Lyell’s Syndrome) with Intravenous Human Immunoglobulins. Burns, 27, 652-655. https://doi.org/10.1016/S0305-4179(01)00005-5</mixed-citation></ref><ref id="scirp.120358-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Bastuji-Garin, S., et al. (1993) Toxic Epidermal Necrolysis (Lyell Syndrome) in 77 Elderly Patients. Age and Ageing, 22, 450-456. https://doi.org/10.1093/ageing/22.6.450</mixed-citation></ref><ref id="scirp.120358-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Bonnetblanc, J.M., Vaillant, L. and Wolkenstein, P. (1995) Facteurs prédisposant des réactions cutanées aux médicaments. Annales de Dermatologie et de Vénéréologie, 122, 484-486.</mixed-citation></ref><ref id="scirp.120358-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Elboraey, M.O. and Essa, E.E.S.F. (2021) Steven-Johnson Syndrome Post Second Dose of Pfizer COVID-19 Vaccine: A Case Report. Oral Surgery Oral Medicine Oral Pathology Oral Radiology, 132, e139-e142. https://doi.org/10.1016/j.oooo.2021.06.019</mixed-citation></ref><ref id="scirp.120358-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Mardani, M., Mardani, S., Kani, Z.A. and hakanifard, A. (2022) An Extremely Rare Mucocutaneous Adverse Following COVID-19 Vaccination: Toxic Epidermal Necrolysis. Dermatologic Therapy, 35, e15416. https://doi.org/10.1111/dth.15416</mixed-citation></ref><ref id="scirp.120358-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Dash, S., Sirka, C.S., Mishra, S. and Viswan, P. (2021) COVID-19 Vaccine Induced Steven-Johnson Syndrome: A Case Report. Clinical and Experimental Dermatology, 46, 1615-1617. https://doi.org/10.1111/ced.14784</mixed-citation></ref><ref id="scirp.120358-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Halebian, P.H., et al. (1993) A Burn Center Experience: Toxic Epidermal Necrolysis. Dermatology, 186, 32-37. https://doi.org/10.1159/000247299</mixed-citation></ref><ref id="scirp.120358-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Barbaud, A. (2004) Toxidermies immunoallergiques chez l’immunocompétent. EMC-Dermatologie-Cosmétologie, 1, 75-86. https://doi.org/10.1016/j.emcdc.2003.11.001</mixed-citation></ref><ref id="scirp.120358-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Saiag, P., Roujeau, J.-C. and Touraine, R. (1988) Syndrome de Lyell. La Revue Du Praticien-Dermatologie, 38, 1617-1622.</mixed-citation></ref><ref id="scirp.120358-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Bachot, N. and Roujeau, J.-C. (2003) Differential Diagnosis of Severe Cutaneous Drug Eruptions. American Journal of Clinical Dermatology, 4, 561-572. https://doi.org/10.2165/00128071-200304080-00006</mixed-citation></ref><ref id="scirp.120358-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Mercier, E., Gissot, V., Legars, A., Dequin, D.F. and Perrotin, D. (2001) Syndrome de Lyell et hépatite fulminante après traitement par léflunomide. La Revue de Médecine Interne, 22, 486s-487s. https://doi.org/10.1016/S0248-8663(01)80139-9</mixed-citation></ref><ref id="scirp.120358-ref20"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Barnoud</surname><given-names> D.</given-names></name>,<name name-style="western"><surname> Boulétreau</surname><given-names> P.</given-names></name>,<name name-style="western"><surname> Piquet</surname><given-names> M. A.</given-names></name>,<name name-style="western"><surname> &amp; Vermesch</surname><given-names> R. </given-names></name>,<etal>et al</etal>. (<year>2003</year>)<article-title>. In-dications à la nutrition entéraleenréanimation, aspects quantitatifset-qualitatifs</article-title><source> Réanimation</source><volume> 12</volume>,<fpage> 355</fpage>-<lpage>359</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.120358-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Mokline, A., Rahmani, I., Garsallah, L., Tlaili, S., Hammouda, R. and Messadi, A.A. (2016) La nécrolyse épidermique toxique. The Annals of Fires and Burn Disaster, 29, 37-40.</mixed-citation></ref><ref id="scirp.120358-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Roujeau, J.C., Guillaume, J.C., Fabre, J.P. and Penso, D. (1990) Toxic Epidermal Necrolysis (Lyell syndrome): Incidence and Drug Etiology in France, 1981-1985. Archives of Dermatology, 126, 37-42. https://doi.org/10.1001/archderm.1990.01670250043005</mixed-citation></ref><ref id="scirp.120358-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Roujeau, J.C., Kelly, J.P., Naldi, L. and Rzany, B. (1995) Medication Use and the Risk of Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis. New England Journal of Medicine, 333, 1600-1608. https://doi.org/10.1056/NEJM199512143332404</mixed-citation></ref><ref id="scirp.120358-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Wolkenstein, P.E., Roujeau, J.C. and Revuz, J. (1998) Drug-Induced Toxic Epidermal Necrolysis. Clinics in Dermatology, 16, 399-408.https://doi.org/10.1016/S0738-081X(98)00011-X</mixed-citation></ref><ref id="scirp.120358-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Correia, O., Chosidow, O., Saiag, P. and Bastuji-Garin, S. (1993) Evolving Pattern of Drug-Induced Toxic Epidermal Necrolysis. Dermatology, 186, 32-37. https://doi.org/10.1159/000247299</mixed-citation></ref><ref id="scirp.120358-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Lissia, M., Mulas, P., Bulla, A. and Rubino, C. (2010) Toxic Epidermal Necrolysis (Lyell’s disease). Burns, 36, 152-163. https://doi.org/10.1016/j.burns.2009.06.213</mixed-citation></ref><ref id="scirp.120358-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Surbled, M., Lejus, C., Milpied, B. and Pannier, M. (1996) Syndrome de Lyell consécutif à l’administration d’amoxicilline chez un enfant de 2 ans. Annales Francaises d’Anesthésie et de Réanimation, 15, 1095-1098. https://doi.org/10.1016/S0750-7658(96)89482-2</mixed-citation></ref><ref id="scirp.120358-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Melde, S.L. (2001) Ofloxacin: A Probable Cause of Toxic Epidermal Necrolysis. Annals of Pharmacotherapy, 35, 1388-1390. https://doi.org/10.1345/aph.1Z433</mixed-citation></ref><ref id="scirp.120358-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Mandal, B., Steward, M., Singh, S. and Jones, H. (2004) Nécrolyse épidermique toxique induite par la ciprofloxacine (NET) chez un nonagréen: A propos d’un cas. Age Vieillissement, 33, 405-406.</mixed-citation></ref><ref id="scirp.120358-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Mame Thierno, D., On, S. and Thierno Ndiaye, S. (2001) Syndrome de Lyell au Sénégal: Responsabilité de la thiacétazone. Annales de Dermatologie et de Vénéréologie, 128, 1305-1307.</mixed-citation></ref><ref id="scirp.120358-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Wetterwald, E., Chosidow, O., Bachot, N., Roujeau, J.C. (2001) Syndrome de Lyell (nécrolyse épidermique toxique). Encyclopédie Médico-Chirurgicale. Dermatologie, A-10, 98-270.</mixed-citation></ref><ref id="scirp.120358-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Roujeau, J.C., Chosidow, O., Saiag, P. and Guillaume, J.C. (1990) Toxic Epidermal Necrolysis (Lyell Syndrome). Journal of the American Academy of Dermatology, 23, 1039-1058. https://doi.org/10.1016/0190-9622(90)70333-D</mixed-citation></ref><ref id="scirp.120358-ref33"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Roujeau</surname><given-names> J.C. </given-names></name>,<etal>et al</etal>. (<year>2007</year>)<article-title>Nécrolyse épidermique toxique et syndrome de Stevens-Johnson</article-title><source> Révérend Prat</source><volume> 57</volume>,<fpage> 1165</fpage>-<lpage>1170</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.120358-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Khoo, A.K. and Foo, C.I. (1996) Nécrolyse épidermique toxique dans un centre de grands brulés: Bilan sur 6 ans. Brulures, 22, 275-278.</mixed-citation></ref><ref id="scirp.120358-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Ying, S.Y., Ho, W.S. and Chan, H.H. (2001) Toxic Epidermal Necrolysis: 10 Years Experience of a Burns Centre in Hong Kong. Burns, 27, 372-375. https://doi.org/10.1016/S0305-4179(00)00136-4</mixed-citation></ref><ref id="scirp.120358-ref36"><label>36</label><mixed-citation publication-type="book" xlink:type="simple">Lipman, T.O. (2002) Nutrition Support for the Critically Ill: Parenteral, Enteral or None. In: Nitenberg, G., Chioléro, R. and Leverve, X., Eds., Nutrition artificielle de l’adulte en réanimation, Elsevier, Paris, 135-150.</mixed-citation></ref></ref-list></back></article>